Breadcrumb Navigation

Dotatate PET

68Ga-DOTATATE PET/CT is the most sensitive exam to detect well-differentiated neuroendocrine tumors. Since these tumors have a low glucose consumption but high expression of somatostatine receptors (SSTR) on their surface, 68Ga-DOTATATE is superior to 18F-FDG for tumor detection. This new method has replaced the Octreotide scintigraphiy in our clinic, due to a higher sensitivity and an improved localization of the SSTR positive lesion, thanks to the CT component.

Dotatate PET in Onkology

On the axial fused images, a focal DOTATATE accumulation in the pancreas can be localized (red arrow), which corresponds to a small neuroendocrine tumor that could not be delineated with the CT. There is also a lymph node metastasis dorsal to the pancreas (yellow arrow).
On the axial fused images, a focal DOTATATE accumulation in the pancreas can be localized (red arrow), which corresponds to a small neuroendocrine tumor that could not be delineated with the CT. There is also a lymph node metastasis dorsal to the pancreas (yellow arrow).

Indications

The following indication is reimbursed by the health insurance:

  • Staging, restaging and diagnosis of recurrence of differentiated neuroendocrine tumors (e.g. also before and after 117Lu-DOTATATE therapy).
Details see PDF, page 105ff

Dotatate PET in Neurooncology

In the brain, 68Ga-DOTATATE-PET / CT is suitable for the clarification of meningiomas and meningioma recurrences, e.g. before radiation planning.

High tracer uptake in the meningioma
High tracer uptake in the meningioma

Indications

The following indication is reimbursed by the health insurance:

  • Therapy planning for meningioma
Details see PDF, page 105ff

Responsible doctors

Martin Hüllner, PD Dr. med.

Senior Attending Physician, Department of Nuclear Medicine
Deputy Clinic Director, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
Diagnostic Neuroradiologist, Department of Nuclear Medicine

Specialties: Oncological, neurological and musculoskeletal imaging
Tel. +41 44 255 25 80

Lars Husmann, Prof. Dr. med.

Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine

Specialties: PET/CT Imaging
Tel. +41 43 253 87 99

David Kenkel, PD Dr. med.

Attending Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine

Specialties: Oncological imaging (PET, SPECT, CT, MRI)

Cäcilia Mader, Dr. med.

Senior Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
Neuroradiologist, Department of Nuclear Medicine

Specialties: Oncological, neurological and musculoskeletal hybrid imaging
Tel. +41 43 253 88 02

Alexander Maurer, Dr. med.

Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine

Specialties: Oncologic imaging, Hybrid imaging of prostate cancer
Tel. +41 43 253 88 09

Michael Messerli, PD Dr. med.

Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine

Specialties: Hybrid imaging of oncological diseases (PET, SPECT, CT, MRI)
Tel. +41 43 253 88 03

For patients

As a patient, you cannot register directly for a consultation. Please have your family doctor, specialist refer you. If you have any questions, please use our contact form.

Tel. +41 44 255 35 55

For referring physicians

Simply assign your patient via registration form.

Tel. +41 44 255 35 55

Medical information hotline: 08.00-18.00 o’clock: +41 44 255 15 02